Roche said a new weight-loss pill under development achieved positive results in an early-stage clinical trial, bolstering the company’s efforts to enter the obesity market.
Shares of Novo Nordisk (NVO) and Eli Lilly (LLY) are sliding after Roche (ROG.SW, RBO.PA) reported promising early-stage trial data from its weight-loss pill. Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the trial results and…
EL PASO, Texas (KVIA) -- A federal court just sentenced 22-year-old El Pasoan Michael Joseph Cuccaro to 15 years in prison for selling a fake M-30 oxycodone pill to a person who ended up dying from fentanyl poisoning. The sale happened…
The 20th century saw humanity develop in leaps and bounds, and without a doubt one of the most revolutionary advances was oral contraceptives, more commonly known as "the pill."
Shares of weight-loss drugmakers including Eli Lilly, Novo Nordisk and Structure Therapeutics fell on Wednesday after Roche Holding announced positive early-stage trial data for its experimental obesity pill.
Patients taking Roche’s experimental drug, in the same class as injectables like Ozempic, Wegovy, Mounjaro and Zepbound, lost an average of 6% of their starting bodyweight after a month.
The common pill taken by millions already is believed to block triggering proteins and douses inflammation - which plays a key role in ovarian cancer. It could protect those with a family history of the disease
In a disturbing turn of events in Mumbai, a pregnant woman tragically lost her life after allegedly being forced by her husband and stepson to consume abortion pills.